PRESS RELEASE FundaMental Pharma Appoints Industry Veteran Dr. Lorenz Mayr as Non-Executive Director Appointment underscores FundaMental’s ambition to develop medicines for neurodegenerative diseases based on a breakthrough molecular mechanism Heidelberg, GERMANY, 20 March 2024 - FundaMental Pharma GmbH, a neuroscience company developing first-in-class small molecule inhibitors for the treatment of a range of neurodegenerative diseases, announced today the appointment of Dr.

新闻稿基础制药任命行业资深人士Lorenz Mayr博士为非执行董事任命强调了基础制药基于突破性分子机制开发神经退行性疾病药物的雄心壮志，德国海德堡，2024年3月20日-基础制药股份有限公司，一家开发用于治疗一系列神经退行性疾病的一流小分子抑制剂的神经科学公司，今天宣布任命博士。

Lorenz Mayr to its Board of Directors. Lorenz is a highly respected biopharmaceutical executive with extensive experience over the last 30 years in drug discovery, technology and innovation, business growth and financing strategy. He currently serves on the Board of Directors at Phoremost (Cambridge, UK), Mogrify (Cambridge, UK), InCephalo (Basel, Switzerland), the Scientific Advisory Board of Fraunhofer IGB & IPA (Stuttgart, Germany), Fraunhofer IZI (Leipzig, Germany) and SaxoCell (Leipzig), The Francis Crick Institute (London, UK), Medicines Discovery Catapult (Alderley Park, UK), LenioBio (Düsseldorf, Germany), SensibleBio (Oxford, UK), and works as Senior Healthcare Advisor to EQT Investments (Stockholm/Sweden).

洛伦兹·梅尔（LorenzMayr）向董事会致辞。洛伦兹是一位备受尊敬的生物制药高管，在过去30年中在药物发现、技术和创新、业务增长和融资策略方面拥有丰富经验。他目前担任Phoremost（英国剑桥）、Mogrify（英国剑桥）、InCephalo（瑞士巴塞尔）、Fraunhofer IGB&IPA（德国斯图加特）、Fraunhofer IZI（德国莱比锡）和SaxoCell（莱比锡）的董事会成员，Francis Crick Institute（英国伦敦）、Medicines Discovery Catapult（英国奥尔德利公园）、LenioBio（德国杜塞尔多夫）、SensibleBio（英国牛津）的科学顾问，并担任EQT Investments（斯德哥尔摩/瑞典）的高级医疗顾问。

Most recently, Lorenz was CEO of Vector BioPharma (Basel, Switzerland). He has held various other senior executive roles in companies such as Bayer, Novartis, AstraZeneca, GE Healthcare and Syncona. Previously, he was Chief Technology Officer at GE Healthcare Life Sciences, where he was responsible for R&D strategy and innovation across all life sciences business areas.

最近，洛伦兹是Vector BioPharma（瑞士巴塞尔）的首席执行官。他曾在拜耳（Bayer）、诺华（Novartis）、阿斯利康（AstraZeneca）、通用电气（GE Healthcare）和Syncona等公司担任过其他各种高级管理职务。此前，他担任GE Healthcare Life Sciences的首席技术官，负责所有生命科学业务领域的研发战略和创新。

Lorenz has extensive global experience in pharmaceutical R&D, including positions as Vice President & Global Head at AstraZeneca and Executive Director at Novartis and Bayer Pharmaceuticals. Lorenz obtained a Ph.D. in Bio.

洛伦兹在药物研发方面拥有丰富的全球经验，包括担任阿斯利康副总裁兼全球负责人以及诺华和拜耳制药的执行董事。洛伦兹获得了生物学博士学位。